SCHEMBL852338

SCHEMBL852338

CCOC(=N)c1ccc(Oc2ccc(C(=O)NC3CCN(CCCN)CC3)c(Oc3ccc(C(=N)OCC)cc3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ST14 Q9Y5Y6 9/20 0.61
F10 P00742 8/20 0.61
F2 P00734 7/20 0.61
PRSS1 P07477 6/20 0.55
PRSS2 P07478 6/20 0.55
PRSS3 P35030 6/20 0.55
PLG P00747 1/20 0.44
SMYD3 Q9H7B4 1/20 0.40
SLC6A5 Q9Y345 1/20 0.39
HPGDS O60760 1/20 0.38
HSD11B1 P28845 1/20 0.38
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL851827 0.89 ST14 (0.75) ST14F10F2PRSS1PRSS2
SCHEMBL851051 0.85 ST14 (0.76) ST14F10F2PRSS1PRSS2
SCHEMBL851279 0.82 ST14 (0.78) ST14F10F2PRSS1PRSS2
SCHEMBL851171 0.82 F10 (0.76) ST14F10F2PRSS1PRSS2
SCHEMBL851756 0.76 F10 (0.79) ST14F10F2PRSS1PRSS2
SCHEMBL850854 0.76 ST14 (1.00) ST14F10F2PRSS1PRSS2
SCHEMBL850827 0.74 F10 (0.57) ST14F10F2PRSS1PRSS2
SCHEMBL850652 0.74 F10 (0.58) ST14F10F2PRSS1PRSS2
SCHEMBL850881 0.73 ST14 (0.73) ST14F10F2PRSS1PRSS2
SCHEMBL851516 0.71 ST14 (1.00) ST14F10F2PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140200225-A1 PROTEASE INHIBITORS ORION CORPORATION (FI) 2014-07-17 US disclosed
US-8722930-B2 Protease inhibitors ORION CORPORATION (FI) 2014-05-13 US disclosed
US-20120136002-A1 PROTEASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-05-31 US disclosed
EP-2432556-A1 PROTEASE INHIBITORS Orion Corporation (FI) 2012-03-28 EP disclosed
US-20110082151-A1 SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR AUSPEX PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
WO-2010133748-A1 PROTEASE INHIBITORS ORION CORPORATION (FI) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200225-A1 PROTEASE INHIBITORS SERPINB1, TMPRSS15, PRSS1 ST14 216/4885F10 152/4885F2 112/4885
US-20110082151-A1 SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR EDNRA, EDNRB, GLP1R ST14 1574/4885F10 3438/4885F2 4442/4885
US-20120136002-A1 PROTEASE INHIBITORS SERPINB1, TMPRSS15, PRSS1 ST14 216/4885F10 152/4885F2 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.